iFIT Mission Statement

Our Cluster of Excellence teams world-leading expertise in three important areas of cancer research which have so far been largely separated. Their combination promises an unprece­dented level of understanding of tumor biology and the development of novel diagnostic and therapeutic approaches for tumor diseases. These areas include A) the identification of “functionally instructed molecular therapies” via functional genomics, B) their combination with and further development of advanced immunotherapies and C) the use of multiparametric imaging techniques to guide tumor therapies and to unravel novel classes of therapeutic targets.

The iFIT consortium aims to:

  • functionally identify biological processes in tumors which can be exploited for the development of novel cancer therapies;
  • explore immunotherapy resistance using functional genomic screening to develop advanced cancer immunotherapies, particularly combinatorial immunotherapies and combinations with molecularly targeted therapies;
  • advance multiparametric imaging to quantify and temporally resolve key molecular and immunological processes in tumor maintenance, progression and therapy response by using novel methods and biomarkers to unravel novel classes of therapeutic targets;
  • personalize function-based molecular and immunotherapies and develop combinations there­of through temporally and spatially resolved image guidance.

Participating institutions in Germany

  • University of Tübingen
  • University Hospital Tübingen
  • Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (IKP), Stuttgart, Germany
  • Natural and Medical Sciences Institute at the University of Tübingen (NMI), Reutlingen
  • German Cancer Consortium (DKTK), Heidelberg, Germany
  • Max Planck Institute for Developmental Biology, Tübingen, Germany
  • Max Planck Institute for Intelligent Systems, Tübingen, Germany

Cooperation partners

  • Cancer Research UK, Cambridge and London, UK
  • CeGaT GmbH, Tübingen, Germany
  • CureVac AG, Tübingen, Germany
  • Diamond Light Source, Oxfordshire, UK
  • Immatics Biotechnologies GmbH, Tübingen, Germany
  • Johns Hopkins University, Baltimore, USA
  • LassBio Institute of the University of Rio de Janeiro, Rio de Janeiro, Brazil
  • Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany
  • MRC London Institute of MEdical Sciences, London, UK
  • Memorial Sloan Kettering Center, New York, USA
  • Moffitt Cancer Center, Tampa, USA
  • Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen (NMI), Reutlingen, Germany
  • Netherlands Cancer Institute, Amsterdam, Netherlands
  • Synimmune GmbH, Tübingen, Germany
  • The Institute Pasteur, Paris, France
  • The Research Institute of Molecular Pathology (IMP), Vienna, Austria
  • University of Aarhus, Aarhus, Denmark
  • University of California, Davis, San Diego, San Francisco, USA
  • University of Cambridge, Cambridge, UK
  • University of Frankfurt, Frankfurt, Germany
  • University of Montreal, Montreal, Canada
  • University of North Carolina at Chapel Hill, Chapel Hill, USA
  • University of Texas MD Anderson Cancer Center, Houston, USA
  • University of Würzburg, Würzburg, Germany